Cargando…

Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors

Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, peripheral and/or axial spondyloarthritis, Crohn’s disease, and ulcerative colitis, are characterized by molecular and cellular changes in the immune system. Due to the systemic nature of these diseases, organs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muth, Katharina N., Rech, Juergen, Losch, Florian O., Hoerning, André
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419406/ https://www.ncbi.nlm.nih.gov/pubmed/37568441 http://dx.doi.org/10.3390/jcm12155039

Ejemplares similares

Estimation of Serum 1,25-Dihydroxycholecalciferol and Tumor Necrosis Factor-α Levels in Chronic Periodontitis
por: Dhulipalla, Ravindranath, et al.
Publicado: (2023)

Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
por: Oh, Gyu Man, et al.
Publicado: (2020)

Tumor necrosis factor‐α inhibitor‐induced follicular psoriasiform eruption
por: Goldberger, Tal, et al.
Publicado: (2022)

Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study
por: Claßen, Merle, et al.
Publicado: (2022)

Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor
por: Soucy-Giguere, Marie-Camille, et al.
Publicado: (2019)

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
por: Gareb, Bahez, et al.
Publicado: (2020)

NOTCH2 sensitizes the chondrocyte to the inflammatory response of tumor necrosis factor α
por: Canalis, Ernesto, et al.
Publicado: (2023)

Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation
por: Washburn, Newell R., et al.
Publicado: (2013)

Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy
por: Bielewicz-Zielińska, Agnieszka, et al.
Publicado: (2015)

Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment
por: Takazono, Takahiro, et al.
Publicado: (2016)

Acquired epidermodysplasia verruciformis in setting of tumor necrosis factor-α inhibitor therapy
por: Schultz, Brittney, et al.
Publicado: (2018)

Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study
por: Dalén, Johan, et al.
Publicado: (2020)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
por: Al-Meghaiseeb, Ebtissam Saleh, et al.
Publicado: (2016)

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa
por: Soto Lopes, Marien Siqueira, et al.
Publicado: (2013)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
por: Desai, Rishi J., et al.
Publicado: (2014)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications
por: Kang, Elise, et al.
Publicado: (2018)

Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy
por: Takahashi, Gen, et al.
Publicado: (2019)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis
por: Hagino, Teppei, et al.
Publicado: (2023)

Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies
por: Claßen, Merle, et al.
Publicado: (2023)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
por: Lee, Jee Un, et al.
Publicado: (2017)

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
por: Mantravadi, Santhi, et al.
Publicado: (2020)

Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events
por: Kunchok, Amy, et al.
Publicado: (2020)

Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis
por: Lee, Sang-Oh
Publicado: (2013)

Recurrent Streptococcus agalactiae Toxic Shock Syndrome Triggered by a Tumor Necrosis Factor-α Inhibitor
por: Yoshida, Masataka, et al.
Publicado: (2016)

Protective effect of etanercept, an inhibitor of tumor necrosis factor-α, in a rat model of retinal ischemia
por: Bae, Hyoung Won, et al.
Publicado: (2016)

Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-α inhibitor
por: Leman, Ryan Edrick, et al.
Publicado: (2017)

Clinical features of tumor necrosis factor-α-inhibitor induced chilblain lupus: A case series
por: Shabeeb, Nadine, et al.
Publicado: (2021)

Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients
por: Hachisu, Yoshimasa, et al.
Publicado: (2019)

Tumor necrosis factor receptor I, II and tumor necrosis factor-α levels in patients with burns
por: Endo, S, et al.
Publicado: (2000)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Salivary tumor necrosis factor-α and periodontal destruction
por: Tin, Sim Sai, et al.
Publicado: (2015)

Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology
por: Salomon, Benoît L., et al.
Publicado: (2018)

Tumor necrosis factor α Inhibition for Alzheimer’s Disease
por: Chang, Rudy, et al.
Publicado: (2017)

Tumor Necrosis Factor-α: The Next Marker of Stroke
por: Xue, Yimeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58o8m2ic8ar9jdg4b4g1p26g80